These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 16681280)

  • 1. Million dollar miracles.
    Smith SD
    Minn Med; 2006 Apr; 89(4):30-5, 51. PubMed ID: 16681280
    [No Abstract]   [Full Text] [Related]  

  • 2. In that case.
    Anderson L; Cunningham N
    J Bioeth Inq; 2005; 2(2):109. PubMed ID: 16317869
    [No Abstract]   [Full Text] [Related]  

  • 3. Response.
    McPherson J
    J Bioeth Inq; 2005; 2(2):114-5. PubMed ID: 16317874
    [No Abstract]   [Full Text] [Related]  

  • 4. Response.
    Denholm J
    J Bioeth Inq; 2005; 2(2):112-3. PubMed ID: 16317872
    [No Abstract]   [Full Text] [Related]  

  • 5. Who should receive recombinant factor VIII?
    Giangrande PL
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S25-7. PubMed ID: 9351533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant clotting factors in the treatment of hemophilia.
    Lee C
    Thromb Haemost; 1999 Aug; 82(2):516-24. PubMed ID: 10605745
    [No Abstract]   [Full Text] [Related]  

  • 7. Response.
    Newell C
    J Bioeth Inq; 2005; 2(2):113. PubMed ID: 16317873
    [No Abstract]   [Full Text] [Related]  

  • 8. Response.
    Carnahan M
    J Bioeth Inq; 2005; 2(2):110-1. PubMed ID: 16317870
    [No Abstract]   [Full Text] [Related]  

  • 9. Participation in research: the economic advantages in a haemophilia research population.
    Wasserman J; Ullman M; Cantini M; Moynihan K; Hoots WK
    Haemophilia; 2000 Sep; 6(5):571-4. PubMed ID: 11012704
    [No Abstract]   [Full Text] [Related]  

  • 10. Who should be liable for funding recombinant factor VIII?
    Richards RG
    BMJ; 1998 May; 316(7141):1385-6. PubMed ID: 9564004
    [No Abstract]   [Full Text] [Related]  

  • 11. New therapeutic products and difficult decisions. The case of recombinant factor VIII in the management of haemophilia A.
    Green C; Akehurst R
    J Public Health Med; 1998 Jun; 20(2):137-8. PubMed ID: 9675729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health status in Iranian haemophilic patients.
    Karimi M; Rahmani S; Ardeshiri R; Pasalar M
    Haemophilia; 2008 May; 14(3):615-7. PubMed ID: 18393983
    [No Abstract]   [Full Text] [Related]  

  • 13. Recombinant factor VIII in hemophilia.
    Cohen A; Butler R
    N Engl J Med; 1991 May; 324(21):1515-6. PubMed ID: 1902552
    [No Abstract]   [Full Text] [Related]  

  • 14. Prophylaxis vs. episodic treatment to prevent joint disease in severe hemophilia.
    Bernstein MJ
    N Engl J Med; 2007 Nov; 357(20):2087; author reply 2087-8. PubMed ID: 18003967
    [No Abstract]   [Full Text] [Related]  

  • 15. Hemophilia market awaits next-generation therapies.
    Sheridan C
    Nat Biotechnol; 2011 Nov; 29(11):960. PubMed ID: 22068523
    [No Abstract]   [Full Text] [Related]  

  • 16. Factor VIII: maximal benefit?
    Nour-Eldin F
    Eur J Med; 1992 Apr; 1(1):55-7. PubMed ID: 1341979
    [No Abstract]   [Full Text] [Related]  

  • 17. How we choose factor VIII to treat hemophilia.
    Mannucci PM; Mancuso ME; Santagostino E
    Blood; 2012 May; 119(18):4108-14. PubMed ID: 22411872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing the costs for clinical care of patients with high-responding factor VIII and IX inhibitors.
    Ullman M; Hoots WK
    Haemophilia; 2006 Dec; 12 Suppl 6():74-9; discussion 79-80. PubMed ID: 17123398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factor VIII inhibitor and severity of hemophilia.
    Schoppmann A; Waytes AT
    Thromb Haemost; 1996 Aug; 76(2):280-1. PubMed ID: 8865549
    [No Abstract]   [Full Text] [Related]  

  • 20. From cow's milk to medicine chest.
    Brown SF
    Fortune; 2000 Sep; 142(5):52, 54, 56. PubMed ID: 11183603
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.